Similarly, the CARES-310 trial investigates the combination of camrelizumab, a PD-L1 inhibitor given at 200 mg every 2 weeks, with rivoceranib, a VEGFR inhibitor taken at 250 mg orally four times daily, suggesting a synergistic approach to disrupt tumor microenvironments. Here, KDR is linked to neoplasm.